Exelixis, Inc. (EXEL)

NASDAQ: EXEL · IEX Real-Time Price · USD
22.60
+0.04 (0.18%)
At close: Jul 19, 2024, 4:00 PM
22.19
-0.41 (-1.81%)
After-hours: Jul 19, 2024, 5:21 PM EDT
0.18%
Market Cap 6.58B
Revenue (ttm) 1.85B
Net Income (ttm) 205.05M
Shares Out 291.29M
EPS (ttm) 0.64
PE Ratio 35.31
Forward PE 16.21
Dividend n/a
Ex-Dividend Date n/a
Volume 1,294,088
Open 22.57
Previous Close 22.56
Day's Range 22.53 - 22.75
52-Week Range 18.64 - 24.34
Beta 0.54
Analysts Buy
Price Target 26.64 (+17.88%)
Earnings Date Jul 30, 2024

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2000
Employees 1,310
Stock Exchange NASDAQ
Ticker Symbol EXEL
Full Company Profile

Financial Performance

In 2023, Exelixis's revenue was $1.83 billion, an increase of 13.60% compared to the previous year's $1.61 billion. Earnings were $207.77 million, an increase of 13.98%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $26.64, which is an increase of 17.88% from the latest price.

Price Target
$26.64
(17.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on ...

7 weeks ago - Business Wire

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectivel...

2 months ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences i...

2 months ago - Business Wire

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives...

2 months ago - Business Wire

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:...

3 months ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences i...

5 months ago - Business Wire

Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments

Exelixis Inc. (EXEL, Financial) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to treat patients with various types of cancer.

5 months ago - GuruFocus

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key cor...

5 months ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences i...

6 months ago - Business Wire

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezo...

6 months ago - Business Wire

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will be released on Tuesday, February 6, 2024 after the m...

6 months ago - Business Wire

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against thre...

6 months ago - Business Wire

BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis

Full rights returned following Exelixis' corporate restructuring announced January 07, 2024 Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics LUND, SWEDEN / ...

6 months ago - Accesswire

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2023, provided financial guidance for fiscal year 2024 a...

7 months ago - Business Wire

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview...

7 months ago - Business Wire

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, fro...

8 months ago - Business Wire

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab vers...

8 months ago - Business Wire

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

ALAMEDA, Calif. and HAYWARD, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration...

Other symbols: RCUS
8 months ago - Business Wire

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tu...

8 months ago - Business Wire

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previousl...

9 months ago - Business Wire

Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on progress toward achieving key corporate objecti...

9 months ago - Business Wire

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two...

9 months ago - Business Wire

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close. A...

9 months ago - Business Wire

Exelixis to license Insilico AI-designed cancer drug

Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insilico Medicine's generative artificial intelligence ...

11 months ago - Market Watch

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

ALAMEDA, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granti...

11 months ago - Business Wire